Monoclonal Antibodies Market Share, Size, Trends, Industry Analysis Report, Source Type (Chimeric, Murine, Humanized, Human); By Production Type (In Vivo, In Vitro); By Application; By End-use; By Region; Segment Forecast, 2022 - 2030

Monoclonal Antibodies Market Share, Size, Trends, Industry Analysis Report, Source Type (Chimeric, Murine, Humanized, Human); By Production Type (In Vivo, In Vitro); By Application; By End-use; By Region; Segment Forecast, 2022 - 2030

The global Monoclonal Antibodies market size is expected to reach USD 479.13 billion by 2030, according to a new study by Polaris Market Research. The report “Monoclonal Antibodies Market Share, Size, Trends, Industry Analysis Report, By Source Type (Chimeric, Murine, Humanized, Human), By Production Type (In Vivo, In Vitro), By Application, By End-use, By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides an analysis of future market growth.

The increasing uses of mAb therapies, rising government initiatives in infection control and management, and growing cancer incidences, with the demand for cost-effective biosimilar monoclonal antibodies, are the major factors driving the market. In addition, the high demand for biologics, the expansion of genomics R&D activities, and the introduction of technologically advanced genetic platforms like next-generation sequencing also spur market growth.

Furthermore, the monoclonal antibody market has grown due to the COVID-19 virus outbreak. Effective treatments are required due to the sudden increase in individuals with COVID-19 and the mortality risk associated with the illness. Additionally, due to their potential to reduce disease burden, numerous industry participants are consistently working to create novel mAb for the prevention and treatment of the COVID-19 virus. These antibodies are an efficient alternative for decreasing COVID-19, and the US FDA has given emergency use authorizations (EUA) for several of these antibodies.

Monoclonal Antibodies Market Report Highlights

• In 2021, the human source category segment had the most significant proportion. Human monoclonal antibody product approvals and an increase in medicine launches contribute to the segment’s growth. The market for this segment is predicted to grow due to human mAb in treating numerous infectious diseases.
• The low levels of contamination provided by the method and the availability of improved biomanufacturing capabilities made in vitro production type the dominant type in 2021.
• Due to the increasing number of mAb cancer therapies that have received approval, as well as growing public and scientific knowledge of these treatments, the oncology segment held the majority of the market in 2021.
• Use of monoclonal antibodies for cancer treatment in hospitals and rising healthcare spending that favors the adoption of such medicines, hospitals made up the highest proportion of the end-use segment in 2021.
• North America held the largest market share owing to Increasing Industry R&D spending and government financing for cancer research, which have aided in developing innovative monoclonal antibody treatments.
• Major players operating in the industry include Abbott Laboratories, Amgen Inc, AstraZeneca plc, Bayer AG, Biogen Inc., Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc, Sanofi S.A., Thermo Fisher Scientific, Inc.,and Viatris Inc.

Polaris Market Research has segmented the Monoclonal Antibodies Market report based on raw material, type, technology, end-use, and region:

Monoclonal Antibodies, Source type Outlook (Revenue – USD Billion, 2018 – 2030)

• Murine
• Chimeric
• Humanized
• Human

Monoclonal Antibodies, Production Type Outlook (Revenue – USD Billion, 2018 – 2030)

• In Vivo
• In Vitro

Monoclonal Antibodies Application Outlook (Revenue – USD Billion, 2018 – 2030)

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Neurological Diseases
• Others

Monoclonal Antibodies, End-Use Outlook (Revenue – USD Billion, 2018 – 2030)

• Hospitals
• Specialty Centers
• Others

Monoclonal Antibodies, Regional Outlook (Revenue – USD Billion, 2018 – 2030)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa